FDA Turns Off Otsuka’s Abilify Dimmer Switch Graphic
This article was originally published in The Pink Sheet Daily
Executive Summary
As lights go out on the franchise, FDA says pharmacology aid misleadingly suggests Abilify offers advantages over other treatments.
You may also be interested in...
DTC Safety Messages Could Vary By Platform As FDA Considers Screen Size
Both tablets and huge TVs have proliferated since the last research of the impact of superimposed text.
FDA's Rx Promotion Citation Drought Continued In 2015
First Amendment litigation and guidance document work may be factors behind decline.
FDA Cites Akorn’s Exhibit Banner At ASHP Clinical Conference
Booth promotion for Nembutal fails to disclose any risk information, Office of Prescription Drug Promotion says in the fifth letter issued this year.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: